Promsin MasrinoulOrapim PuipromAtsushi TanakaMiwa KuwaharaPanjaporn ChaichanaKazuyoshi IkutaPongrama RamasootaTamaki OkabayashiMahidol UniversityOsaka University2018-11-092018-11-092014-01-01Virology. Vol.464-465, No.1 (2014), 111-11710960341004268222-s2.0-84904874174https://repository.li.mahidol.ac.th/handle/123456789/34017Chikungunya virus (CHIKV) causes an acute clinical illness characterized by sudden high fever, intense joint pain, and skin rash. Recent outbreaks of chikungunya disease in Africa and Asia are a major public health concern; however, there is currently no effective licensed vaccine or specific treatment. This study reported the development of a mouse monoclonal antibody (MAb), CK47, which recognizes domain III within the viral envelope 1 protein and inhibited the viral release process, thereby preventing the production of progeny virus. The MAb had no effect on virus entry and replication processes. Thus, CK47 may be a useful tool for studying the mechanisms underlying CHIKV release and may show potential as a therapeutic agent. © 2014 Elsevier Inc.Mahidol UniversityImmunology and MicrobiologyArticleSCOPUS10.1016/j.virol.2014.05.038